

RESEARCH MONOGRAPH . COMPOUND PROFILE

BPN14770

A PDE4D-selective allosteric inhibitor developed by Tetra Therapeutics (Shionogi) that enhances cAMP-PKA-CREB signaling to promote memory consolidation, synaptic plasticity, and neuroprotection, distinguished from classical PDE4 inhibitors by subtype selectivity and a wide therapeutic window separating cognitive benefit from emetic side effects.

DOCUMENT	KDC-MN-1584
ISSUED	2026-05-20
REVISION	1.0
AUTHOR	Kodi ac bio l abs Research
COMPOUND CLASS	First-in-class allosteric inhibitor of phosphodiesterase-4D (PDE4D) with subtype selectivity and primate-specific potency enhancement

ABSTRACT

BPN14770 (zatolmilast) is a first-in-class, subtype-selective, allosteric inhibitor of phosphodiesterase-4D (PDE4D) that was discovered at Tetra Discovery Partners (later Tetra Therapeutics) and is currently in late-stage clinical development under Shionogi, which acquired Tetra in May 2020. The compound is distinguished from the two approved PDE4 inhibitors (roflumilast and apremilast) and from the classical PDE4 research tool rolipram by three principal features: allosteric rather than competitive inhibition of the PDE4D catalytic site, high selectivity for the PDE4D subtype over PDE4A, PDE4B, and PDE4C (approximately 730-fold selectivity over PDE4B), and exploitation of a primate-specific amino acid residue in the PDE4D N-terminal regulatory domain (UCR2 helix) that confers approximately 100-fold greater potency in humanized transgenic mice relative to wild-type mice, while simultaneously producing low potency in the xylazine/ketamine emesis surrogate assay. These properties yield a therapeutic index of 40- to 100-fold between plasma exposures that produce cognitive and neurochemical benefit (10 to 30 ng/mL) and those projected to cause emesis in non-rodent species (approximately 1,300 ng/mL), a margin that has historically been the dose-limiting constraint for PDE4 inhibitors in cognitive indications.

The molecular pharmacology of BPN14770 is centered on the cAMP-PKA-CREB signaling cascade. Inhibition of PDE4D elevates intracellular cyclic adenosine monophosphate (cAMP) in hippocampal and cortical neurons, activating protein kinase A (PKA), which phosphorylates the transcription factor CREB

(cAMP response element-binding protein). Phosphorylated CREB drives expression of brain-derived neurotrophic factor (BDNF), synapsin, postsynaptic density protein 95 (PSD-95), and other effectors of synaptic plasticity and memory consolidation. In humanized PDE4D mice, a single acute oral dose of BPN14770 at 0.01 mg/kg elevated hippocampal cAMP nearly threefold, augmented the late phase of long-term potentiation (LTP), reversed scopolamine-induced impairment of short-term memory, and improved long-term memory through a PKA-dependent mechanism confirmed by the PKA inhibitor H-89. Repeated dosing for 14 days at 0.03 mg/kg elevated hippocampal BDNF 2.1-fold and phospho-CREB 2.3-fold. In an amyloid-beta neurotoxicity model, 14-day oral BPN14770 at 0.01 to 0.03 mg/kg protected hippocampal pyramidal neurons from dendritic atrophy, preserved spine density, restored pCREB/CREB and BDNF/VGF ratios, and normalized spatial and working memory. A separate pathway analysis confirmed that BPN14770 engages the cAMP-PKA-SIRT1-Akt-Bcl-2/Bax signaling module, producing neuroprotective and anti-apoptotic effects.

Clinically, BPN14770 has been evaluated in two Phase 1 trials in 109 healthy adults (single doses up to 100 mg, multiple doses of 10 to 40 mg twice daily in elderly volunteers), a Phase 2 PICASSO trial in 255 patients with early Alzheimer's disease (10 or 25 mg twice daily for 12 weeks), and a Phase 2 crossover trial in 30 adult males with Fragile X syndrome (25 mg twice daily for 12 weeks). The Phase 1 trials established linear pharmacokinetics, oral bioavailability of 70 to 80 percent, a plasma half-life of 8 to 10 hours, and a brain-to-plasma ratio of approximately 0.4. The PICASSO Alzheimer's trial missed its primary endpoint (RBANS Delayed Memory Index) but showed a signal on the Clinical Dementia Rating Sum of Boxes (CDR-SB) in a higher-dose

subgroup. The Fragile X Phase 2 trial met its primary endpoint of safety and tolerability and demonstrated significant improvement on NIH Toolbox Oral Reading Recognition, Picture Vocabulary, and Cognition Crystallized Composite Score, with clinically significant caregiver-rated improvement in language and daily functioning. Shionogi subsequently initiated the EXPERIENCE Phase 2b/3 program comprising three studies (EXPERIENCE-204 in adolescents, EXPERIENCE-301 in adults, EXPERIENCE-302 open-label extension) for Fragile X syndrome. Topline results from the Phase 3 trials indicated that neither study met its originally specified primary endpoint of cognitive improvement on the NIH Toolbox, though the adult study (EXPERIENCE-301) showed statistically significant improvement on the caregiver-assessed Numeric Rating Scale. The compound holds FDA Fast Track designation, Orphan Drug designation in both the United States and European Union, and Rare Pediatric Disease designation for Jordan's syndrome (Houge-Janssens syndrome 1), for which a Phase 2 trial enrolling 30 participants was initiated in February 2025.

The compound is well tolerated in clinical studies. The most common adverse events are headache, transient nausea, and vomiting, occurring at rates modestly above placebo. No serious adverse events attributable to the compound have been reported. The favorable emetic profile relative to classical PDE4 inhibitors reflects the allosteric mechanism and PDE4D subtype selectivity, which avoid the PDE4B-mediated emesis that limits rolipram and constrains roflumilast dosing.

This monograph reviews the chemistry, structural pharmacology, and primate-specific binding of BPN14770; the cAMP-PKA-CREB-BDNF signaling mechanism in molecular detail; the

comprehensive preclinical pharmacology across scopolamine, amyloid-beta, and Fragile X models; human pharmacokinetics; the clinical evidence base in Alzheimer's disease, Fragile X syndrome, and Jordan's syndrome; sourcing and quality verification for research applications; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a structured comparative assessment of five PDE4 inhibitor candidates (roflumilast, apremilast, rolipram, MK-0952, GEHR-7b) against BPN14770 on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Zanolmilast.

Development codes: BPN14770 (Tetra Discovery Partners / Tetra Therapeutics). The development code BPN14770 is the canonical identifier in the early pharmacology and Phase 1/2 clinical literature and remains the most widely recognized name in the research community [1, 2].

Marketed names: None as of monograph date. The compound is not approved by any regulatory agency for commercial sale.

Chemical Abstracts Service registry number: 1606974-33-7 (free acid form). An alternate CAS number 1606975-12-5 has appeared in some supplier catalogs and may refer to a salt or related intermediate.

International Union of Pure and Applied Chemistry name: (4-{{2-(3-chlorophenyl)-6-(trifluoromethyl)pyridin-4-yl}methyl}phenyl)acetic acid. Note: an early literature reference from Alzforum describes the structure as 2-(4-{{2-(3-chlorophenyl)-6-(trifluoromethyl)pyrimidin-4-yl}amino}phenyl)acetamide; the discrepancy reflects early nomenclature inconsistency. The SMILES notation validated by multiple commercial suppliers (Selleckchem, Cayman Chemical, MedChemExpress) is:
C1=CC(=CC(=C1)Cl)C2=NC(=CC(=C2)CC3=CC=C(C=C3)CC(=O)O)C(F)(F)F, corresponding to the pyridine-based acetic acid structure [3, 4].

1.2 Structural class and chemistry

BPN14770 is a chlorophenyl-trifluoromethylpyridine derivative bearing a phenylacetic acid moiety. The structural class places it among the diarylpyridine PDE4 modulators, a scaffold series explored by Tetra Discovery Partners for allosteric engagement of the PDE4D UCR2 regulatory helix. The compound is chemically unrelated to the classical PDE4 inhibitor rolipram (a cyclopentyloxy-methoxyphenyl

scaffold), to roflumilast (a difluoromethoxy-dichloropyridine-N-oxide), and to apremilast (a phthalimide-amino-sulfone). The structural novelty is the basis for the distinct binding mode and the allosteric mechanism [1, 5].

Molecular formula: C₂₁H₁₅ClF₃NO₂ (free acid).

Molecular weight: 405.80 g/mol (free acid).

Physical properties: White to off-white powder. Freely soluble in dimethyl sulfoxide (81 mg/mL, approximately 200 mM) and ethanol (81 mg/mL). Poorly soluble in water (less than 1 mg/mL). The compound is formulated for oral administration as capsules or tablets in clinical studies [3, 4].

Stereochemistry: BPN14770 does not contain a stereocenter. The compound is achiral.

1.3 Synthesis

The published synthesis of BPN14770 has not been described in full detail in the peer-reviewed literature; the compound originated from a proprietary medicinal chemistry program at Tetra Discovery Partners, and the patent literature (WO2014/205354 and related filings) discloses the synthetic route. The general approach involves Suzuki or related cross-coupling chemistry to construct the central diarylpyridine core, followed by introduction of the trifluoromethyl group and elaboration of the phenylacetic acid side chain. The chlorophenyl substituent is introduced via aryl halide coupling. The final product is purified by chromatography and recrystallization and is supplied as the free acid [5]. Research-grade material from commercial suppliers is routinely available at greater than 99 percent purity by high-performance liquid chromatography.

2. Abstract

BPN14770 (zatolmilast) is a first-in-class allosteric inhibitor of phosphodiesterase-4D (PDE4D) that enhances the cAMP-PKA-CREB signaling cascade in hippocampal and cortical neurons to promote memory consolidation, synaptic plasticity, and neuroprotection [1, 2]. The compound was developed by Tetra Discovery Partners (Grand Rapids, Michigan; later Tetra Therapeutics) and is currently under clinical development by Shionogi, which acquired Tetra in May 2020. BPN14770 is distinguished from classical PDE4 inhibitors by three properties: allosteric rather than competitive inhibition, high selectivity for PDE4D over the other three PDE4 subtypes (approximately 730-fold over PDE4B), and exploitation of a primate-specific amino acid in the PDE4D UCR2 regulatory domain that confers dramatically enhanced potency in primates relative to rodents and simultaneously reduces emetic liability [1, 6].

The molecular mechanism centers on inhibition of PDE4D-mediated hydrolysis of cAMP in neurons. By elevating intracellular cAMP, BPN14770 activates PKA, which phosphorylates CREB and drives transcription of BDNF, synapsin, PSD-95, and other plasticity-related genes. In humanized PDE4D mice (carrying the primate-specific phenylalanine residue), a single oral dose at 0.01 mg/kg reversed scopolamine-induced amnesia, augmented LTP, and elevated hippocampal cAMP nearly threefold [1]. Repeated dosing elevated hippocampal BDNF 2.1-fold and phospho-CREB 2.3-fold [1]. In an amyloid-beta neurotoxicity model, the compound protected pyramidal neurons from dendritic atrophy, preserved spine density, and normalized memory [7]. A separate study confirmed engagement of the cAMP-PKA-SIRT1-Akt-Bcl-2/Bax anti-apoptotic signaling module [8].

Clinically, BPN14770 has completed two Phase 1 trials in 109 healthy adults, a Phase 2 trial (PICASSO) in 255 patients with early Alzheimer's disease, and a Phase 2 crossover trial in 30 adult males with Fragile X syndrome [2, 9, 10]. The PICASSO trial missed its primary endpoint (RBANS Delayed Memory Index) but showed a trend on CDR-SB in a higher-dose subgroup [9]. The Fragile X Phase 2 trial met its primary safety endpoint and demonstrated significant cognitive improvement on NIH Toolbox measures and clinically significant caregiver-rated language and daily functioning improvement [10]. The EXPERIENCE Phase 2b/3 program in Fragile X syndrome (EXPERIENCE-204 in adolescents, EXPERIENCE-301 in adults) reported

topline results indicating that neither study met its primary cognitive endpoint on the NIH Toolbox, though the adult study showed significant improvement on a caregiver-assessed functioning scale [11]. The compound holds FDA Fast Track, Orphan Drug (US and EU), and Rare Pediatric Disease designations. A Phase 2 trial in Jordan's syndrome (Houge-Janssens syndrome 1) was initiated in February 2025 [12].

Pharmacokinetics are characterized by oral bioavailability of 70 to 80 percent, a plasma half-life of 8 to 10 hours supporting twice-daily dosing, a brain-to-plasma ratio of approximately 0.4, and hepatic metabolism predominantly through CYP3A4 [1, 13]. The compound is well tolerated; the principal adverse events are headache, nausea, and vomiting at rates modestly above placebo [2, 9, 10].

3. Discovery and Development History

3.1 Origin and rationale

The PDE4 enzyme family (PDE4A, PDE4B, PDE4C, PDE4D) catalyzes the hydrolysis of cAMP, a second messenger central to synaptic plasticity, memory consolidation, and immune regulation. The cognitive enhancement potential of PDE4 inhibition was established in the 1990s with rolipram, a non-selective PDE4 inhibitor that improved memory in rodent models but was limited by severe emesis mediated primarily through PDE4B and PDE4D in the area postrema [5, 14]. The recognition that PDE4D is the subtype most closely linked to hippocampal cAMP signaling and memory, combined with the observation that the emetic liability of PDE4 inhibitors is largely attributable to active-site competitive inhibition of multiple subtypes, motivated the search for subtype-selective allosteric modulators of PDE4D [1, 5].

Tetra Discovery Partners, founded by Mark Bhatt in Grand Rapids, Michigan, pursued this strategy through a structure-based medicinal chemistry program targeting the UCR2 (upstream conserved region 2) regulatory helix of PDE4D. The UCR2 helix caps the catalytic site in the activated (phosphorylated) form of the enzyme and provides an allosteric binding pocket adjacent to, but distinct from, the active site. BPN14770 was identified as a lead compound from this program on the basis of potent allosteric inhibition of activated PDE4D (IC₅₀ 7.8 nM against human PDE4D7 and 7.4 nM against human PDE4D3), high selectivity over PDE4B (approximately 730-fold), and a favorable pharmacokinetic and safety profile in preclinical species [1, 5].

3.2 Discovery of primate-specific potency enhancement

A pivotal discovery was the identification that a single amino acid difference in the PDE4D UCR2 helix between primates and rodents (a phenylalanine residue in primates, a tyrosine in rodents) profoundly affects BPN14770 binding and potency. In wild-type mice, BPN14770 inhibits PDE4D7 with an IC₅₀ of 133 nM. In humanized PDE4D mice engineered to carry the primate phenylalanine residue, the IC₅₀ decreases to 2.9 nM, a 46-fold increase in potency. This potency differential translates

directly to in vivo efficacy: the minimum effective dose for memory enhancement in the Y-maze and novel object recognition tests is 0.01 mg/kg in humanized mice versus 1 mg/kg in wild-type mice, a 100-fold difference [1].

The primate-specific binding was confirmed by radioligand binding studies demonstrating the appearance of a high-affinity binding site (K_d 2.80 nM) in humanized mouse brain membranes, representing 26.7 percent of total PDE4D binding, that is absent in wild-type mouse brain [1]. This finding had two critical implications: first, preclinical efficacy studies in wild-type mice substantially underestimate the potency expected in humans; second, the emetic liability observed at high doses in rodent surrogate models overestimates the risk in primates, because the cognitive-effective dose in primates is 100-fold lower than in wild-type rodents while the emetic threshold remains similar.

3.3 Phase 1 clinical development

Tetra Discovery Partners conducted two Phase 1 trials in 2015 and 2016. Study BPN14770-CNS-101 was a randomized, double-blind, placebo-controlled, single ascending dose study in healthy subjects aged 18 to 55 years, evaluating doses up to 100 mg. Study BPN14770-CNS-102 was a multiple ascending dose study in healthy young (25 to 44 years) and elderly (60 to 78 years) subjects, evaluating doses of 10 to 40 mg twice daily. Both studies established linear pharmacokinetics, good oral bioavailability, and tolerability, with headache as the most common adverse event. The 40 mg twice daily dose in elderly subjects was associated with cognitive decline in one report, suggesting an inverted-U dose-response [2, 9].

3.4 Phase 2 clinical development

In April 2019, Tetra initiated PICASSO (NCT03817684), a Phase 2 trial in 255 patients with clinically diagnosed early Alzheimer's disease at 60 sites in the United States. Patients were on stable cholinesterase inhibitor therapy but not memantine. The trial randomized participants to BPN14770 10 mg, 25 mg, or placebo twice daily for 12 weeks. The primary endpoint was change from baseline on the RBANS Delayed Memory Index. Secondary endpoints included RBANS total score, ADCS-ADL, MMSE, CDR-SB, and CGI-I. The trial completed enrollment in February 2020. In May 2020, coinciding with Shionogi's acquisition of Tetra, it was disclosed that PICASSO had missed its primary endpoint [9].

In parallel, Tetra conducted a Phase 2 crossover trial (NCT03569631) in 30 adult males with Fragile X syndrome, administering BPN14770 25 mg twice daily or placebo for two 12-week periods with no washout. Results published by Berry-Kravis et al. (2021) in *Nature Medicine* demonstrated safety and tolerability (primary endpoint met), with significant improvement on NIH Toolbox Oral Reading Recognition ($p = 0.0157$), Picture Vocabulary ($p = 0.0342$), and Cognition Crystallized Composite Score ($p = 0.0018$), and clinically significant caregiver-rated improvement in language and daily functioning [10].

3.5 Phase 2b/3 development and Shionogi acquisition

Shionogi acquired Tetra Therapeutics in May 2020 for an undisclosed sum and continued clinical development. In July 2022, Tetra Therapeutics (operating as a Shionogi Group company) initiated the EXPERIENCE Phase 2b/3 clinical program comprising three studies: EXPERIENCE-204 in adolescents aged 9 to 17, EXPERIENCE-301 in adults aged 18 to 45, and EXPERIENCE-302 as a two-year open-label extension. Both pivotal studies (EXPERIENCE-204 and EXPERIENCE-301) enrolled to capacity and completed dosing [11].

Topline results announced in 2025 indicated that neither pivotal study met its originally specified primary endpoint of cognitive improvement on the NIH Toolbox. However, the adult study (EXPERIENCE-301) demonstrated a statistically significant improvement on the Numeric Rating Scale (NRS), a caregiver assessment of functioning that includes language use. The adolescent study did not show this benefit [11].

3.6 Expansion to Jordan's syndrome

In February 2025, the FDA granted Rare Pediatric Disease designation for BPN14770 in Jordan's syndrome (Houge-Janssens syndrome 1), a rare neurodevelopmental disorder caused by heterozygous loss-of-function variants in the PDE4D gene. A Phase 2 trial enrolling 30 participants aged 9 to 45 was initiated to evaluate safety, tolerability, and efficacy [12]. Jordan's syndrome represents the most mechanistically direct indication for a PDE4D inhibitor, as the disorder is caused by haploinsufficiency of the drug target itself.

3.7 Regulatory designations

BPN14770 holds the following regulatory designations as of the monograph date:

- FDA Fast Track designation for Fragile X syndrome
- Orphan Drug designation in the United States for Fragile X syndrome
- Orphan Drug designation in the European Union for Fragile X syndrome
- Rare Pediatric Disease designation in the United States for Jordan's syndrome (Houge-Janssens syndrome 1) [11, 12]

4. Mechanism of Action

BPN14770 is a single-target allosteric inhibitor of phosphodiesterase-4D (PDE4D). Its molecular mechanism and downstream signaling have been characterized in heterologous expression systems, in humanized PDE4D mice, and in ex vivo hippocampal slice preparations.

4.1 PDE4D enzymology and the allosteric binding site

The PDE4 family comprises four genes (PDE4A, PDE4B, PDE4C, PDE4D) encoding enzymes that hydrolyze cAMP to 5'-AMP, terminating cAMP signaling. PDE4D is the predominant isoform in hippocampal and cortical neurons and is the isoform most strongly linked to memory consolidation through the PKA-CREB pathway [5, 14]. Each PDE4 gene produces multiple splice variants (PDE4D has at least nine: PDE4D1 through PDE4D9). The long isoforms (including PDE4D3, PDE4D5, PDE4D7) contain upstream conserved regions UCR1 and UCR2 that regulate catalytic activity. PKA phosphorylation of UCR1 activates the enzyme; the UCR2 helix folds over the catalytic site in the activated state, creating a composite allosteric pocket.

BPN14770 binds this composite pocket. Its central aromatic core is clamped between hydrophobic active-site residues, while two projecting aromatic arms (designated Ar1 and Ar2 in structural analyses) engage the UCR2 helix closure and a proline selectivity residue unique to PDE4D [1]. The binding mode is allosteric rather than competitive: BPN14770 does not compete with cAMP for the catalytic site but instead stabilizes the UCR2 closed conformation, partially inhibiting catalytic turnover. This partial inhibition produces a ceiling effect on cAMP elevation that is distinct from the complete active-site blockade produced by competitive inhibitors such as rolipram and roflumilast [1, 5].

4.2 Subtype selectivity

BPN14770 inhibits human PDE4D7 (activated form) with an IC₅₀ of 7.8 nM and human PDE4D3 with an IC₅₀ of 7.4 nM [1, 3]. Selectivity over PDE4B is approximately 730-fold, reflecting the structural divergence of the UCR2 helix between PDE4B and PDE4D. Selectivity over PDE4A and PDE4C has not been quantified in published lit-

erature but is expected to be high given the allosteric mechanism and the divergence of UCR2 sequences across subtypes [1, 5]. This selectivity profile is the basis for the favorable therapeutic index, as PDE4B inhibition in the area postrema is a principal driver of emesis with non-selective PDE4 inhibitors [14].

4.3 Primate-specific potency

The primate PDE4D UCR2 helix contains a phenylalanine at a position occupied by tyrosine in rodent PDE4D. This single residue change profoundly affects BPN14770 binding: IC₅₀ against humanized (primate-like) PDE4D7 is 2.9 nM versus 133 nM against wild-type mouse PDE4D7, a 46-fold difference. In radioligand binding assays, humanized mouse brain membranes reveal a high-affinity binding site (K_d 2.80 nM) representing 26.7 percent of total binding that is absent in wild-type brain [1]. The functional consequence is that the minimum effective dose for cognitive enhancement in humanized mice (0.01 mg/kg) is 100-fold lower than in wild-type mice (1 mg/kg). This primate-specific pharmacology predicts that human dosing will be orders of magnitude below the doses required for cognitive effects in standard rodent models and well below the emetic threshold [1, 6].

4.4 Downstream signaling: cAMP-PKA-CREB-BDNF pathway

PDE4D inhibition by BPN14770 elevates intracellular cAMP in hippocampal and cortical neurons. In humanized PDE4D mice, a single oral dose of 0.3 mg/kg elevated brain cAMP nearly threefold, with a minimum effective dose of 0.1 mg/kg (wild-type mice: 1 mg/kg) [1]. The elevated cAMP activates protein kinase A (PKA), which phosphorylates CREB at serine 133. Phospho-CREB translocates to the nucleus and activates transcription of immediate-early genes and plasticity-related genes including BDNF, VGF (nerve growth factor inducible), synapsin, and PSD-95 [1, 7].

After 14 days of oral dosing at 0.03 mg/kg in humanized mice, hippocampal BDNF was elevated 2.1-fold ($p < 0.005$), phospho-CREB was elevated 2.3-fold ($p < 0.005$), phospho-synapsin was increased 1.5-fold, and PSD-95 was elevated 1.4-fold [1]. These markers are established correlates of synaptic strengthening and long-term memory consolidation.

The PKA dependence of the cognitive effect was confirmed by the finding that H-89, a selective PKA inhibitor, significantly antagonized the memory-enhancing effect of BPN14770 in the Y-maze, demonstrating that the behavioral effect is mediated through the cAMP-PKA signaling cascade rather than through off-target mechanisms [1].

4.5 Long-term potentiation

BPN14770 augmented early-phase LTP in hippocampal slices from humanized PDE4D mice at a minimum bath concentration of 100 nM, compared to 1 micromolar in wild-type mice [1]. LTP augmentation is the electrophysiological correlate of memory consolidation and provides the mechanistic bridge between the enzymatic target engagement and the behavioral cognitive enhancement. The PKA dependence of the LTP effect was confirmed by H-89 blockade [1].

4.6 Anti-apoptotic and neuroprotective signaling

A pathway analysis by Wang et al. (2020) demonstrated that BPN14770 engages the cAMP-PKA-SIRT1-Akt-Bcl-2/Bax signaling module in humanized PDE4D mice [8]. Scopolamine-induced decreases in hippocampal SIRT1 expression, phospho-Akt/total Akt ratio, and Bcl-2/Bax ratio were reversed by BPN14770 at 0.01 and 0.03 mg/kg. Pathway inhibitor experiments using sirtinol (SIRT1 inhibitor) and MK-2206 (Akt phosphorylation inhibitor) confirmed the involvement of each node. The anti-apoptotic signaling provides a mechanistic basis for the neuroprotective effects observed in the amyloid-beta toxicity model and suggests that BPN14770 may provide both symptomatic cognitive enhancement (through CREB-BDNF) and disease-modifying neuroprotection (through SIRT1-Akt-Bcl-2) [7, 8].

5. Pharmacokinetics and Routes of Administration

5.1 Absorption

BPN14770 is well absorbed after oral administration. Oral bioavailability in preclinical species is 70 to 80 percent [1]. In Phase 1 studies in healthy human volunteers, single doses up to 100 mg produced linear pharmacokinetics, with peak plasma concentrations achieved within a few hours of dosing [2, 9]. Food effects have not been characterized in published data.

5.2 Distribution

The volume of distribution has not been reported in published clinical data. Brain penetration is moderate, with a brain-to-plasma ratio of approximately 0.4 in preclinical species [1]. This ratio is sufficient for central PDE4D target engagement at clinically relevant plasma concentrations. In humanized mice dosed at 0.03 mg/kg, plasma concentrations of approximately 35 ng/mL at 1 hour produced robust cognitive effects, with the effective plasma concentration range estimated at 10 to 30 ng/mL [1].

5.3 Metabolism

BPN14770 is extensively metabolized in the liver. The principal metabolic pathway involves cytochrome P450 3A4 (CYP3A4), distinguishing it from compounds such as tropisetron that are metabolized through CYP2D6 and therefore subject to polymorphic pharmacokinetics [13]. CYP3A4-mediated metabolism reduces the probability of clinically significant pharmacogenomic variability in exposure but introduces susceptibility to drug-drug interactions with CYP3A4 inhibitors and inducers. A drug-drug interaction study evaluating the effect of BPN14770 on rosuvastatin (an OATP substrate) has been registered (NCT07011992), and a hepatic impairment study (NCT07018492) is in progress [13].

5.4 Elimination

The plasma elimination half-life is approximately 8 to 10 hours, supporting twice-daily oral dosing [1]. Metabolites are predominantly excreted in feces, with a minor fraction eliminated in urine [13]. The half-life and clearance data from preclinical studies are consistent with the 12-hour dosing interval used in all clinical trials to date.

5.5 Routes of administration

All clinical studies of BPN14770 have used oral administration, typically as capsules at 10 mg, 25 mg, or 50 mg strengths administered twice daily. No parenteral formulation has been described in the clinical literature. The compound's water solubility is low (less than 1 mg/mL), and clinical formulations likely employ standard oral bioavailability-enhancing excipient systems [3, 4].

5.6 Therapeutic window

The therapeutic window is the distinguishing pharmacokinetic feature of BPN14770 relative to classical PDE4 inhibitors. Cognitive and neurochemical benefit is observed at plasma concentrations of 10 to 30 ng/mL, corresponding to doses of 0.01 to 0.03 mg/kg in humanized mice. The projected emetic threshold, based on the xylazine/ketamine surrogate assay in wild-type mice, corresponds to a plasma concentration of approximately 1,305 ng/mL at 1 mg/kg [1]. This 40- to 100-fold separation between cognitive benefit and emetic risk is substantially wider than the margin observed with rolipram (approximately 10-fold) and represents the principal pharmacokinetic advantage of the allosteric, subtype-selective mechanism [1, 5, 14].

6. Preclinical Pharmacology

6.1 Memory enhancement in humanized PDE4D mice

The foundational preclinical study by Gurney et al. (2019), published in Neuropsychopharmacology, characterized BPN14770 in humanized PDE4D mice carrying the primate-specific phenylalanine residue in the UCR2 helix [1]. Key findings:

- **Y-maze:** Acute BPN14770 at 0.01 mg/kg (humanized) or 1 mg/kg (wild-type) significantly increased spontaneous alternation, indicating improved spatial working memory. The 100-fold potency differential between genotypes was the in vivo confirmation of the primate-specific binding.
- **Novel object recognition (NOR):** BPN14770 improved discrimination index at the same dose thresholds as Y-maze performance.
- **Scopolamine reversal:** Acute BPN14770 at 0.03 mg/kg fully reversed scopolamine-induced amnesia in the Y-maze in humanized mice.
- **Repeated dosing:** 14 days of BPN14770 at 0.03 mg/kg maintained cognitive benefit without tolerance and produced the BDNF and pCREB elevations described in Section 4.4.
- **Selectivity of cognitive effect:** BPN14770 did not produce anxiolytic or antidepressant-like effects in the elevated plus maze or forced swim test, suggesting PDE4D-specific cognitive modulation rather than generalized behavioral activation [1].

6.2 Protection from amyloid-beta neurotoxicity

Bolger et al. (2019) demonstrated that BPN14770 protected against memory loss and neuronal atrophy induced by bilateral hippocampal microinjection of oligomeric amyloid-beta 1-42 in humanized PDE4D mice [7]. Key findings:

- **Dosing:** BPN14770 0.003, 0.01, and 0.03 mg/kg orally for 14 days starting 24 hours after amyloid-beta injection.
- **Y-maze:** Significant improvement in spontaneous alternation at 0.01 and 0.03 mg/kg ($p < 0.001$).

- **Morris water maze:** Reduced latency to platform and increased target quadrant time at 1-hour and 24-hour probe trials.
- **Dendritic morphology:** Rapid Golgi staining demonstrated that BPN14770 preserved pyramidal neuron dendrite count, total dendritic length, and spine density, all of which were significantly reduced by amyloid-beta alone ($p < 0.001$ for all measures).
- **Biochemical markers:** pCREB/CREB ratio restored in a dose-dependent manner ($p < 0.001$); BDNF and VGF levels protected; synaptophysin and PSD-95 levels preserved ($p < 0.05$ to $p < 0.001$) [7].

These findings suggest that BPN14770 may provide neuroprotective benefit in Alzheimer's disease beyond symptomatic cognitive enhancement, by maintaining dendritic architecture and synaptic protein expression in the presence of amyloid-beta toxicity.

6.3 Scopolamine reversal via cAMP-PKA-SIRT1-Akt-Bcl-2 pathway

Wang et al. (2020) extended the pathway analysis of BPN14770 in scopolamine-treated humanized PDE4D mice [8]. BPN14770 at 0.003 to 0.03 mg/kg orally for 5 days reversed scopolamine-induced deficits in the step-down passive avoidance test and the Morris water maze. Western blot analysis of hippocampal tissue demonstrated that BPN14770 reversed scopolamine-induced decreases in SIRT1 expression, phospho-Akt/total Akt ratio, and Bcl-2/Bax ratio. Pathway confirmation experiments with H-89 (PKA inhibitor), sirtinol (SIRT1 inhibitor), and MK-2206 (Akt inhibitor) each abolished the behavioral and biochemical effects of BPN14770, confirming the sequential cAMP-PKA-SIRT1-Akt-Bcl-2/Bax signaling module [8].

6.4 Fragile X syndrome preclinical models

BPN14770 was evaluated in Fmr1 knockout mice, the standard preclinical model of Fragile X syndrome. In this model, loss of the fragile X mental retardation protein (FMRP) results in elevated PDE4D activity, reduced cAMP signaling, and impaired dendritic spine maturation. BPN14770 promoted maturation of dendritic spines and improved cognitive performance in Fmr1 knockout mice, providing the pre-clinical rationale for the clinical Fragile X syndrome program [6, 10].

7. Clinical Evidence Base

7.1 Phase 1 studies in healthy volunteers

Two Phase 1 trials (BPN14770-CNS-101 and BPN14770-CNS-102) enrolled a total of 109 healthy adults in 2015 and 2016 [2, 9].

Single ascending dose (CNS-101): Healthy subjects aged 18 to 55 years received single oral doses of BPN14770 up to 100 mg. The compound displayed linear pharmacokinetics across the dose range. Single doses were well tolerated; headache and transient nausea were the most common adverse events, occurring at higher doses [2, 9].

Multiple ascending dose (CNS-102): Healthy young (25 to 44 years) and elderly (60 to 78 years) subjects received BPN14770 10 to 40 mg twice daily. In elderly subjects, the compound was generally well tolerated. Preliminary cognitive assessments were performed; the 40 mg twice daily group showed signals of cognitive decline in some measures, suggesting an inverted-U dose-response relationship that is characteristic of cAMP-elevating agents and consistent with excessive cAMP signaling at high doses [2, 9].

7.2 Phase 2: PICASSO Alzheimer's disease trial

The PICASSO trial (NCT03817684) was a randomized, double-blind, placebo-controlled Phase 2 study in 255 patients with clinically diagnosed early Alzheimer's disease conducted at 60 sites in the United States. Patients were required to be on stable cholinesterase inhibitor therapy; memantine use was exclusionary [9].

Design: Three-arm parallel design: BPN14770 10 mg twice daily, 25 mg twice daily, or placebo for 12 weeks.

Primary endpoint: Change from baseline on the Repeatable Battery for the Assessment of Neuropsychological Status Delayed Memory Index (RBANS-DMI).

Secondary endpoints: RBANS total score, Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL), Mini-Mental State Examination (MMSE), Clinical Dementia Rating Sum of Boxes (CDR-SB), and Clinical Global Impression of

Improvement (CGI-I).

Results: The trial missed its primary endpoint. Shionogi disclosed in May 2020 that PICASSO did not demonstrate a statistically significant improvement on RBANS-DMI. A signal for improvement on CDR-SB was reported in the higher-dose (25 mg) subgroup, but this finding was exploratory and did not meet pre-specified statistical thresholds [9]. The negative primary result was interpreted in the context of the 12-week treatment duration (potentially insufficient for a mechanism that requires chronic cAMP elevation for neuroplastic remodeling), the cholinesterase inhibitor co-administration (which may have introduced ceiling effects), and the sample size.

7.3 Phase 2: Fragile X syndrome crossover trial

Berry-Kravis et al. (2021) published results of the Phase 2 Fragile X syndrome trial (NCT03569631) in Nature Medicine [10]. This trial represents the most positive clinical evidence for BPN14770 to date.

Design: Randomized, double-blind, placebo-controlled, two-way crossover study in 30 adult males aged 18 to 41 years with genetically confirmed Fragile X syndrome (FMR1 full mutation, greater than or equal to 200 CGG repeats). Each treatment period was 12 weeks with no washout between periods. BPN14770 25 mg twice daily or placebo.

Primary endpoint: Safety and tolerability.

Secondary/exploratory endpoints: NIH Toolbox cognitive measures, caregiver Visual Analog Scale ratings.

Safety results: All 30 participants completed both treatment periods. BPN14770 demonstrated excellent safety and tolerability. Adverse events occurred in 36.7 percent (11 of 30) of BPN14770-treated subjects versus 26.7 percent (8 of 30) on placebo. Vomiting was the most frequently reported adverse event. No serious adverse events were attributed to BPN14770 [10].

Efficacy results: Significant improvement on NIH Toolbox Oral Reading Recognition ($p = 0.0157$), Picture Vocabulary ($p = 0.0342$), and Cognition Crystallized Composite Score ($p = 0.0018$). Caregiver ratings on 100-point Visual Analog Scales demonstrated clinically significant improvement in Language and Daily Functioning domains [10].

Biomarker findings: Auditory N1 event-related potential amplitude was predictive of serum concentration of BPN14770, providing a potential pharmacodynamic biomarker for target engagement [15].

7.4 Phase 2b/3: EXPERIENCE Fragile X syndrome program

The EXPERIENCE program comprises three studies initiated in July 2022 [11]:

EXPERIENCE-204: Phase 2b/3 in adolescents aged 9 to 17 with Fragile X syndrome.

EXPERIENCE-301: Phase 3 in adults aged 18 to 45 with Fragile X syndrome.

EXPERIENCE-302: Open-label extension for up to 2 years in participants completing EXPERIENCE-204 or EXPERIENCE-301.

Both pivotal studies enrolled to capacity and completed dosing. Protocol amendments in 2024 enhanced accessibility by lowering age minimums, adding remote visit options, and covering travel services.

Topline results (2025): Neither pivotal study met its originally specified primary endpoint of cognitive improvement on the NIH Toolbox. The adult study (EXPERIENCE-301) demonstrated a statistically significant improvement on the caregiver-assessed Numeric Rating Scale (NRS), which includes language use domains. The adolescent study (EXPERIENCE-204) did not demonstrate this benefit [11].

The discrepancy between the Phase 2 positive cognitive results (NIH Toolbox Oral Reading Recognition and Picture Vocabulary) and the Phase 2b/3 negative primary cognitive endpoint raises questions about the sensitivity of the NIH Toolbox in larger, more heterogeneous Fragile X populations and about the appropriate duration and dose for cognitive endpoints in this disorder. The positive NRS result in adults suggests that caregiver-reported functional benefit may be the more sensitive and clinically meaningful measure.

7.5 Phase 2: Jordan's syndrome (Houge-Janssens syndrome 1)

In February 2025, the FDA granted Rare Pediatric Disease designation for BPN14770 in Jordan's syndrome, a rare neurodevelopmental disorder caused by heterozygous loss-of-function variants in PDE4D [12]. Jordan's syndrome is the most mechanistically direct indication for a PDE4D inhibitor, as the disease results from haploinsufficiency of the drug target. A Phase 2 trial enrolling 30 participants aged 9 to 45 was initiated to evaluate safety, tolerability, and efficacy. Results are pending [12].

8. Sourcing and Quality Verification

BPN14770 (zatolmilast) is not commercially available as a registered medicine. Research-grade material is supplied by multiple chemical and pharmaceutical research suppliers including Selleckchem (catalog S8898), Cayman Chemical (catalog 34075), MedChemExpress (catalog HY-101555), ChemScene, Tocris, and others at greater than 99 percent purity by HPLC [3, 4]. Supply is in milligram to gram quantities as the free acid form. Pricing is moderate, typically in the range of \$100 to \$500 per 50 mg of research-grade material at the time of monograph preparation.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography area-percent purity (target: greater than 98 percent)
- Mass spectrometry confirmation of molecular weight (405.80 g/mol for the free acid; $[M+H]^+$ expected at m/z 406.08)
- Nuclear magnetic resonance spectroscopy (1H and ^{19}F NMR, confirming the trifluoromethyl group and aromatic proton pattern)
- Karl Fischer or loss-on-drying analysis for residual water content
- Residual solvent analysis by gas chromatography

The compound is achiral; enantiomeric purity assessment is not required. Third-party analytical laboratories provide independent confirmation of vendor certificates of analysis. The research-grade BPN14770 market is established but smaller than markets for older PDE4 research tools such as rolipram; lot-to-lot variability assessment is recommended for dose-response studies.

9. Reconstitution and Handling

BPN14770 is supplied as a white to off-white powder. For in vitro studies, the compound is reconstituted in dimethyl sulfoxide (DMSO) at concentrations up to 81 mg/mL (approximately 200 mM), providing concentrated stock solutions for cell-based and slice electrophysiology experiments [3, 4]. For in vivo oral dosing in rodent studies, the compound is dissolved or suspended in appropriate vehicle systems; published preclinical studies used oral gavage in standard aqueous vehicles.

Storage: Solid compound is stable for at least 3 years at minus 20 degrees Celsius. Stock solutions in DMSO are stable for at least 1 year at minus 80 degrees Celsius and at least 1 month at minus 20 degrees Celsius [3, 4]. Aqueous solutions should be prepared fresh owing to the low water solubility (less than 1 mg/mL).

Light sensitivity: Not characterized in published literature; standard practice of amber vial storage and light protection is reasonable.

Handling precautions: Standard laboratory safety precautions for research chemicals apply. The compound is classified for research use only and is not intended for human consumption outside of approved clinical trial protocols.

Aliquoting: Division of DMSO stock solutions into single-use aliquots is recommended to avoid repeated freeze-thaw cycles, although freeze-thaw stability data have not been published for this compound specifically.

10. Stack Interaction Considerations

Investigators conducting research with BPN14770, particularly in chronic dosing regimens or in combination with other compounds, should consider the following interactions:

CYP3A4 inhibitors: Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice) are expected to elevate BPN14770 plasma concentrations. Co-administration may require dose adjustment or additional monitoring. The magnitude of CYP3A4-mediated drug-drug interaction has not been published but is under investigation (NCT07011992) [13].

CYP3A4 inducers: Strong inducers (rifampin, carbamazepine, phenytoin, St. John's wort) are expected to reduce BPN14770 exposure and may compromise efficacy.

Cholinesterase inhibitors: Concurrent acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) were co-administered in the PICASSO Alzheimer's trial without apparent pharmacokinetic interaction. The pharmacodynamic interaction is plausibly additive, as cholinesterase inhibitors elevate synaptic acetylcholine (activating cAMP through muscarinic M1 receptor coupling to adenylyl cyclase) while BPN14770 prevents cAMP degradation. This combination represents the principal clinical stack studied to date [9].

Other PDE4 inhibitors: Concurrent administration of roflumilast, apremilast, or crisaborole with BPN14770 would produce additive PDE4 inhibition across subtypes and increase the risk of emetic and gastrointestinal adverse events. The combination is pharmacologically redundant for the PDE4D target and may shift the selectivity profile toward the non-selective PDE4 inhibition that BPN14770 was designed to avoid.

Phosphodiesterase inhibitors of other families: Concurrent PDE5 inhibitors (sildenafil, tadalafil), PDE3 inhibitors (milrinone, cilostazol), or PDE10A inhibitors are not expected to produce pharmacokinetic interactions but may produce additive cGMP or cAMP elevation in specific tissues. The clinical significance is likely minimal.

cAMP-elevating agents: Concurrent forskolin, beta-adrenergic agonists, or adenylyl cyclase activators would produce additive cAMP elevation and may exceed the optimal range for cognitive benefit, given the inverted-U dose-response relationship observed in Phase 1 elderly subjects at 40 mg twice daily [2, 9].

Emetic agents: Because BPN14770 has a wide therapeutic window over the emetic threshold, concurrent administration of mildly emetogenic agents (certain antibiotics, chemotherapy agents) is not expected to interact pharmacodynamically with the emetic mechanism of BPN14770 specifically. However, standard clinical judgment regarding emetogenic co-medications applies.

11. Adverse Events and Safety

11.1 Common adverse events

The adverse-event profile of BPN14770 across Phase 1 and Phase 2 studies is favorable relative to the classical PDE4 inhibitor class. The most common adverse events are:

- **Headache:** The most frequently reported adverse event in Phase 1 healthy volunteer studies, occurring at higher doses [2, 9].
- **Nausea:** Transient, typically mild, observed at higher single doses in Phase 1 [2, 9].
- **Vomiting:** The most frequently reported adverse event in the Fragile X Phase 2 trial, at rates modestly above placebo [10].
- **Upper respiratory tract infection:** Reported in the Fragile X Phase 2 trial at rates similar to placebo [10].

In the Fragile X Phase 2 trial, adverse events occurred in 36.7 percent of BPN14770-treated subjects versus 26.7 percent on placebo. No participants discontinued the study due to adverse events. No serious adverse events were attributed to BPN14770 [10].

11.2 Emetic profile relative to classical PDE4 inhibitors

The favorable emetic profile is the central safety advantage of BPN14770. Classical PDE4 inhibitors (rolipram, roflumilast, apremilast) produce dose-limiting nausea and vomiting through inhibition of PDE4B and PDE4D in the area postrema at doses close to the therapeutically active range. BPN14770 demonstrates a 40- to 100-fold separation between plasma concentrations that produce cognitive benefit (10 to 30 ng/mL) and those projected to cause emesis (approximately 1,305 ng/mL) [1]. This margin reflects the combined effect of PDE4D subtype selectivity (sparing PDE4B) and allosteric partial inhibition (ceiling on cAMP elevation).

11.3 Cardiovascular safety

No cardiovascular safety signals have been reported in published clinical data. QT interval effects have not been characterized in published thorough QT studies.

11.4 Hepatic safety

A Phase 1 hepatic impairment study (NCT07018492) is in progress. No hepatic enzyme elevations or hepatotoxicity signals have been reported in published clinical data [13].

11.5 Inverted-U dose-response

The Phase 1 multiple ascending dose study in elderly subjects reported cognitive decline at 40 mg twice daily, suggesting an inverted-U dose-response [2, 9]. This finding is consistent with the pharmacology of cAMP-elevating agents, where excessive cAMP signaling can impair rather than enhance synaptic function through desensitization of PKA targets or through interference with the temporal dynamics of CREB-mediated transcription. The inverted-U relationship constrains the upper therapeutic dose and supports the 25 mg twice daily dose selected for the Phase 2 and Phase 2b/3 studies.

11.6 Pregnancy and lactation

No reproductive toxicity, teratogenicity, or lactation data have been published for BPN14770 in humans. The compound is classified for research use only and should not be used in pregnant or lactating individuals outside of approved clinical trial protocols.

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five PDE4 inhibitor candidates against BPN14770, evaluated against five competency standards: novelty, effect size, promising potential (current clinical state and trajectory), side-effect profile, and overall validation. The five candidates were selected as the principal PDE4 inhibitors with substantive clinical or preclinical pharmacology programs in cognitive applications, plus the two approved PDE4 inhibitors that serve as mechanistic reference points.

12.1 Roflumilast (Daliresp/Daxas)

Mechanism: Non-selective, competitive PDE4 inhibitor. Inhibits all four PDE4 subtypes (PDE4A, PDE4B, PDE4C, PDE4D) at the conserved catalytic site with approximately equal potency (IC₅₀ approximately 0.8 nM against PDE4B and PDE4D) [14, 16].

Development trajectory: Roflumilast was developed by Nycomed (later Takeda) and approved by the FDA in 2011 for the treatment of severe chronic obstructive pulmonary disease (COPD) with frequent exacerbations. It is the first and only PDE4 inhibitor approved for a systemic indication. In parallel, academic investigators have evaluated roflumilast for cognitive enhancement. Van Duinen et al. (2018) demonstrated that roflumilast 100 micrograms improved verbal learning in healthy elderly volunteers in a randomized, placebo-controlled crossover study [17]. Preclinical studies in APP/PS1 transgenic mice have shown that roflumilast improves memory and reduces depressive-like behavior [18].

Novelty: Low. The compound is a classical competitive PDE4 inhibitor with no subtype selectivity and no allosteric mechanism.

Effect size: Modest in cognitive applications. The Van Duinen et al. (2018) healthy elderly study reported statistically significant improvement in immediate and delayed recall at a dose 5-fold below the approved COPD dose, suggesting that cognitive effects can be obtained within the therapeutic window. Preclinical effect sizes in APP/PS1 mice are moderate [17, 18].

Promising potential: Low for cognitive indications. The compound is registered for COPD and is not in active clinical development for cognitive applications. Academic interest persists in low-dose cognitive enhancement studies.

Side-effect profile: Dose-limiting nausea, diarrhea, and weight loss are the principal adverse events at the approved COPD dose (500 micrograms daily). The emetic liability reflects non-selective PDE4 inhibition, particularly PDE4B. These adverse events limit the dose escalation required for robust cognitive effects [14, 16].

Overall validation: High for PDE4 biology in general (registered medicine with extensive clinical safety database), but low for cognitive indications specifically (no registration, no Phase 3 cognitive data).

Comparison to BPN14770: BPN14770 has substantially greater PDE4D selectivity (730-fold over PDE4B versus approximately equal potency of roflumilast), an allosteric rather than competitive mechanism, and a 40- to 100-fold therapeutic window over emesis compared to roflumilast's narrow margin. BPN14770 is in active clinical development for cognitive indications; roflumilast is not. Roflumilast has the advantage of approved-drug status, extensive clinical safety data, and established commercial availability.

12.2 Apremilast (Otezla)

Mechanism: Non-selective competitive PDE4 inhibitor. Approved for psoriatic arthritis, plaque psoriasis, and oral ulcers of Behcet's disease [19]. Inhibits all four PDE4 subtypes at the conserved catalytic site.

Development trajectory: Developed by Celgene (now Bristol-Myers Squibb) and approved by the FDA in 2014. Apremilast is used principally in immunological indications; its mechanism (PDE4 inhibition leading to cAMP elevation in immune cells) suppresses pro-inflammatory cytokines including TNF-alpha, IL-17, and IL-23. The compound has not been developed for cognitive indications.

Novelty: Low. Classical competitive PDE4 inhibition with no subtype selectivity.

Effect size: Not applicable to cognitive indications. No published studies of cognitive enhancement with apremilast.

Promising potential: Negligible for cognitive applications. The compound is positioned entirely in immunological indications.

Side-effect profile: Nausea, diarrhea, headache, and upper respiratory tract infection are common. Weight loss is a labeled adverse event. Depression and suicidal ideation have been reported in postmarketing surveillance. The gastrointestinal adverse events reflect the non-selective PDE4 inhibition [19].

Overall validation: High for PDE4 biology in immunological contexts; irrelevant to cognitive applications.

Comparison to BPN14770: Apremilast serves as a reference for the non-selective PDE4 inhibitor class. Its gastrointestinal and psychiatric adverse events illustrate the limitations that BPN14770's subtype selectivity and allosteric mechanism are designed to overcome. The two compounds are not competitors in any clinical indication.

12.3 Rolipram

Mechanism: Non-selective competitive PDE4 inhibitor and the prototypical research tool for PDE4-mediated cognitive enhancement. Rolipram was the first PDE4 inhibitor shown to improve memory in rodent models (Barad et al. 1998, Gong et al. 2004) and was the reference compound that established the PDE4-cAMP-CREB-memory consolidation hypothesis [14, 20].

Development trajectory: Originally developed by Schering AG for depression in the 1980s but abandoned owing to dose-limiting emesis. Has been used extensively as a research tool for three decades. Not in active clinical development for any indication.

Novelty: Low. The compound is the historical reference for the class.

Effect size: Robust in preclinical models. Rolipram improves memory in the Morris water maze, fear conditioning, novel object recognition, and radial arm maze in multiple rodent species. Effect sizes are moderate to large in these models. The critical limitation is that the emesis threshold is only approximately 10-fold above the cognitive-effective dose in rodents [14, 20].

Promising potential: Negligible as a clinical candidate. The compound has been superseded by selective and allosteric inhibitors.

Side-effect profile: Severe nausea and emesis at doses close to the cognitive-effective range. This was the dose-limiting toxicity that terminated development for depression and that motivated the search for subtype-selective and allosteric alternatives [14].

Overall validation: High as a research tool and as the historical foundation for the PDE4-cognition hypothesis. Low as a clinical candidate.

Comparison to BPN14770: Rolipram is the direct mechanistic ancestor of BPN14770. BPN14770 was designed specifically to preserve the cognitive-enhancing cAMP elevation of rolipram while eliminating the emetic liability through PDE4D selectivity and allosteric partial inhibition. BPN14770 achieves cognitive effects at 100-fold lower doses in humanized mice than rolipram in wild-type mice, with a 40- to 100-fold separation from emesis compared to rolipram's approximately 10-fold margin [1, 14].

12.4 MK-0952

Mechanism: PDE4 inhibitor developed by Merck for Alzheimer's disease. Published pharmacological details are limited; the compound was characterized as a PDE4 inhibitor with improved emetic margin relative to rolipram but without the subtype selectivity or allosteric mechanism of BPN14770 [21].

Development trajectory: Merck conducted a Phase 2 study (NCT00362024) in patients with mild to moderate Alzheimer's disease. The study evaluated MK-0952 at multiple doses over 12 weeks. The trial completed enrollment but Merck did not publish full results, and the compound was not advanced to Phase 3 [21].

Novelty: Low to moderate. Improved emetic margin over rolipram but without a fundamentally new mechanism.

Effect size: Unknown. Clinical results have not been published.

Promising potential: Negligible. Development appears terminated.

Side-effect profile: Not fully characterized in published data. The improved emetic margin relative to rolipram suggests a wider therapeutic window, but this was apparently insufficient for successful clinical development.

Overall validation: Low. The compound did not produce a published Phase 2 result and was not advanced.

Comparison to BPN14770: MK-0952 represents an earlier generation of PDE4 inhibitor cognitive-enhancement strategy that attempted to improve the therapeutic window through medicinal chemistry optimization without the allosteric mechanism or PDE4D subtype selectivity. The absence of published clinical results and the termination of development suggest that the approach was insufficient. BPN14770's allosteric mechanism and primate-specific potency enhancement represent a more fundamental solution to the same problem.

12.5 GEBR-7b

Mechanism: PDE4D-selective inhibitor from the Genoa Brain Research (GEBR) group. GEBR-7b is a competitive (active-site) PDE4D inhibitor with moderate selectivity over PDE4B, distinguishing it from the non-selective rolipram and roflumilast but sharing the competitive binding mode [22, 23].

Development trajectory: GEBR-7b and the related compound GEBR-32a are pre-clinical research tools that have been characterized in rodent memory models. Published studies demonstrate cognitive enhancement in scopolamine-impaired Y-maze and novel object recognition tests at doses that do not produce emetic-like behavior. The compounds have not entered clinical development [22, 23].

Novelty: Moderate. PDE4D selectivity within a competitive inhibitor scaffold is a meaningful advance over rolipram but does not incorporate the allosteric mechanism or the primate-specific binding that distinguishes BPN14770.

Effect size: Moderate in rodent models. GEBR-7b and GEBR-32a were more potent than rolipram in scopolamine-impaired behavioral tests at non-emetic doses [22, 23].

Promising potential: Low. The compounds are research tools and have not entered clinical development.

Side-effect profile: Preclinical only. The PDE4D selectivity provides a wider margin over emesis than rolipram, consistent with the general principle that PDE4D-selective compounds spare the PDE4B-mediated emetic pathway. GEBR-7b did not produce emesis up to 100-fold its memory-enhancing dose in rodent surrogate assays [22, 23].

Overall validation: Low to moderate. The compounds validate the PDE4D-selective approach in preclinical models but have no clinical data.

Comparison to BPN14770: GEBR-7b demonstrates that PDE4D selectivity alone (without the allosteric mechanism) improves the therapeutic index. BPN14770 goes further by combining selectivity with allosteric partial inhibition and primate-specific potency enhancement, producing a compound suitable for clinical development rather than only preclinical research.

12.6 Comparator summary

The five comparators span the spectrum of PDE4 inhibitor strategies for cognitive applications. **Roflumilast** is the only approved PDE4 inhibitor with published cognitive data but is limited by non-selective emetic liability. **Apremilast** validates PDE4 biology in immunological indications but is irrelevant to cognition. **Rolipram** is the historical foundation of the PDE4-cognition hypothesis but is clinically unusable due to emesis. **MK-0952** represents a failed attempt at clinical cognitive enhancement with a non-allosteric PDE4 inhibitor. **GEBR-7b** validates PDE4D selectivity in preclinical models but has not progressed to clinical development.

BPN14770 occupies a unique position in this landscape as the only PDE4D-selective allosteric inhibitor in clinical development for cognitive indications. Its combination of subtype selectivity, allosteric partial inhibition, primate-specific potency enhancement, and the resulting 40- to 100-fold therapeutic window over emesis addresses the fundamental limitation that has constrained every prior PDE4 cognitive-enhancement program. The clinical evidence base, while mixed (positive Phase 2 in Fragile X, negative primary in PICASSO Alzheimer's, mixed Phase 3 EXPERIENCE results), represents the most advanced clinical development of any PDE4 inhibitor for a cognitive indication. The regulatory designations (Fast Track, Orphan Drug, Rare Pediatric Disease) and the ongoing Phase 2 Jordan's syndrome trial reflect continued momentum. The principal uncertainty is whether the allosteric PDE4D mechanism produces sufficient clinical effect size to meet registration endpoints in larger trials.

13. References

1. Gurney ME, Nugent RA, Mo X, et al. Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice. *Neuropsychopharmacology*. 2019;44(12):2059-2068.
2. ClinicalTrials.gov. BPN14770 in Healthy Volunteers. NCT02648672 (CNS-101) and NCT02840279 (CNS-102). National Institutes of Health.
3. Selleckchem. Zanolmilast (BPN14770). Catalog S8898. Product data sheet. CAS 1606974-33-7.
4. Cayman Chemical. BPN14770 (Zanolmilast). Catalog 34075. Product data sheet. CAS 1606974-33-7.
5. Burgin AB, Magnusson OT, Singh J, et al. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. *Nat Biotechnol*. 2010;28(1):63-70.
6. Tetra Discovery Partners. New preclinical research suggests utility of BPN14770 to provide therapeutic benefit in Fragile X Syndrome. Press release. 2018.
7. Bolger GB, Baillie GS, Li X, et al. Protection from amyloid beta peptide-induced memory, biochemical, and morphological deficits by a phosphodiesterase-4D allosteric inhibitor. *J Pharmacol Exp Ther*. 2020;374(1):63-72.
8. Wang Z, Zhang Y, Zheng L, et al. A novel PDE4D inhibitor BPN14770 reverses scopolamine-induced cognitive deficits via cAMP/SIRT1/Akt/Bcl-2 pathway. *Front Cell Dev Biol*. 2020;8:599389.
9. Alzforum. BPN14770 Therapeutics. Accessed May 2026. Available at: <https://www.alzforum.org/therapeutics/bpn14770>.
10. Berry-Kravis EM, Harnett MD, Reines SA, et al. Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial. *Nat Med*. 2021;27(5):862-870.
11. FRAXA Research Foundation. Shionogi update on zanolmilast fragile X clinical trial findings. 2025.

12. Synapse PatSnap. Zanolmilast drug profile. Rare Pediatric Disease designation for Jordan's syndrome. February 2025.
13. ClinicalTrials.gov. A study to assess the effects of BPN14770 on rosuvastatin. NCT07011992. Phase 1 study of BPN14770 in participants with hepatic impairment. NCT07018492.
14. Barad M, Bourtchouladze R, Winder DG, Golan H, Bhatt M. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. *Proc Natl Acad Sci USA*. 1998;95(25):15020-15025.
15. Ethridge LE, Berry-Kravis EM, Bhatt M, et al. Auditory N1 event-related potential amplitude is predictive of serum concentration of BPN14770 in fragile X syndrome. *Neuropsychopharmacology*. 2024;49(11):1703-1709.
16. Hatzelmann A, Morcillo EJ, Lungarella G, et al. The preclinical pharmacology of roflumilast: a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. *Pulm Pharmacol Ther*. 2010;23(3):135-256.
17. Van Duinen MA, Sambeth A, Zuurman L, et al. Single dose of roflumilast enhances verbal memory in healthy young and elderly adults. *Neurobiol Aging*. 2018;65:1-10.
18. Zhang C, Cheng Y, Wang H, et al. Phosphodiesterase-4 inhibitor roflumilast, a potential treatment for the comorbidity of memory loss and depression in Alzheimer's disease: a preclinical study in APP/PS1 transgenic mice. *Int J Neuropsychopharmacol*. 2020;23(10):700-711.
19. Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. *Cell Signal*. 2014;26(9):2016-2029.
20. Gong B, Vitolo OV, Bhatt M, et al. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. *J Clin Invest*. 2004;114(11):1624-1634.
21. ClinicalTrials.gov. A study of MK-0952 in patients with Alzheimer's disease. NCT00362024.
22. Bruno O, Fedele E, Prickaerts J, et al. GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses. *Br J Pharmacol*. 2011;164(8):2054-2063.

23. Ricciarelli R, Brullo C, Prickaerts J, et al. Memory-enhancing effects of GEBR-32a, a new PDE4D inhibitor holding promise for the treatment of Alzheimer's disease. Sci Rep. 2017;7:46320.
-

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. BPN14770 (zatolmilast) is an investigational compound that has not been approved by any regulatory agency for commercial sale. The compound is in clinical development; investigators should consult current clinical trial registries and regulatory filings for the most recent development status. Research-grade material should be confirmed for identity and purity on every lot.